Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Research Letter

Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes

Authors: P. J. English, A. Ashcroft, M. Patterson, T. M. Dovey, J. C. G. Halford, J. Harrison, D. Eccleston, S. R. Bloom, M. A. Ghatei, J. P. H. Wilding

Published in: Diabetologia | Issue 9/2006

Login to get access

Excerpt

To the Editor: …
Literature
1.
Wing RR, Marcus MD, Epstein LH, Salata R (1987) Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 10:563–566PubMedCrossRef
2.
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed
3.
Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349:941–948PubMedCrossRef
4.
Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef
5.
Wren AM, Small CJ, Abbott CR et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547PubMedCrossRef
6.
Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMedCrossRef
7.
8.
English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP (2002) Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984–2987PubMedCrossRef
9.
Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723PubMedCrossRef
10.
Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224PubMedCrossRef
11.
Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350PubMedCrossRef
12.
Mannucci E, Pala L, Ciani S et al (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48:1168–1172PubMedCrossRef
Metadata
Title
Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes
Authors
P. J. English
A. Ashcroft
M. Patterson
T. M. Dovey
J. C. G. Halford
J. Harrison
D. Eccleston
S. R. Bloom
M. A. Ghatei
J. P. H. Wilding
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0344-y

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Commentary

Latent autoimmune diabetes in adults (LADA)—more than a name

Article

Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3

Article

The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or HLA-DQ genotype

Short Communication

Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?

Article

Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes

Article

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits